# Valiant Thoracic Stent Graft System

| | |
|---|---|
| COMPANY | Medtronic, Inc. |
| PHONE | (888) 283-7868 |
| WEB | www.medtronicendovascular.com |

KEY FEATURES

- Proximal 8-Peak FreeFlo configuration
- Hydrophilic coating on delivery system
- Tip capture for controlled deployment

The Valiant thoracic stent graft with the Captivia delivery system (Medtronic, Inc., Minneapolis, MN) is indicated for endovascular repair of fusiform and saccular aneurysms and penetrating ulcers of the descending thoracic aorta in patients having appropriate anatomy, including: iliac or femoral access vessel morphology that is compatible with vascular access techniques, devices, and/or accessories; nonaneurysmal aortic diameter in the range of 18–42 mm; and nonaneurysmal aortic proximal and distal neck lengths ≥ 20 mm.

The Valiant thoracic stent graft system delivered excellent clinical results through 1 year of patient follow-up in Medtronic's VALOR II pivotal study, a prospective, single-arm study of 160 patients at 24 US medical centers. Designed to evaluate the safety and effectiveness of the Valiant system for TEVAR in the descending thoracic aorta, VALOR II was led by Principal Investigator Ronald Fairman, MD, the Clyde F. Barker–William Maul Measey Professor of Surgery at the Hospital of the University of Pennsylvania. "The VALOR II 12-month results demonstrate that the Medtronic Valiant stent graft is a safe and effective treatment for patients with descending TAAs of degenerative etiology. Through 12 months, there were no cases of rupture or conversion to open surgery. Overall, treatment results were quite promising," Dr. Fairman stated.

# DuraFlow 2 Chronic Hemodialysis Catheter

| | |
|---|---|
| COMPANY | AngioDynamics, Inc. |
| PHONE | (518) 798-1215 |
| WEB | www.angiodynamics.com |

KEY FEATURES

- Convenient, redesigned kit to facilitate inventory control
- Only 48-cm chronic dialysis catheter available
- Thermoplastic polyurethane luer for increased durability
- VP kits provide ideal fit with many currently available medical supply stations

AngioDynamics, Inc. (Latham, NY) announced the US launch of the next-generation DuraFlow 2 chronic hemodialysis catheter and the upcoming launch of the DuraFlow 2 VascPak (VP) kit. Along with the DuraMax chronic hemodialysis catheter, AngioDynamics offers the only 48-cm chronic dialysis catheters on the market, allowing for femoral catheter placements in patients of varying sizes. The DuraFlow 2 catheter continues to provide optimal ease of insertion and sustained high flow rates. A new tough, rigid thermoplastic polyurethane luer increases durability, allowing for more secure fastening to dialysis machines, the company stated.

The VP kit, set for launch in the fiscal 2012 fourth quarter, is designed to meet the needs of many outpatient vascular access centers. Additionally, tray sizes for both the VP and basic kits have been reduced by approximately 30%, providing an ideal fit with popular automated medical supply stations and easier handling and storage.

# TruePath CTO Device

| | |
|---|---|
| COMPANY | Boston Scientific Corporation |
| PHONE | (888) 272-1001 |
| WEB | www.bostonscientific.com/peripheral-interventions |

KEY FEATURES

- Diamond-coated tip
- 0.018-inch wire
- Longest crossing device (165 cm)
- 1:1 torque response
- No capital equipment required

Boston Scientific Corporation (Natick, MA) has announced the United States launch of the TruePath CTO device, which is designed to facilitate the crossing of chronic total occlusions (CTOs) within the peripheral vasculature. The company expects to launch the product in Europe and other international markets in the first half of 2012.

The TruePath CTO device features a rotating diamond-coated tip that is designed to break through occluded peripheral arteries and facilitate the placement of conventional guidewires for treatment of peripheral lesions. The ultra-low 0.018-inch profile is engineered for optimal crossing. Once positioned, the distal tip rotates at 13,000 rpm to facilitate drilling through calcified lesions and other fibrous blockages. The TruePath device requires no capital equipment and is available with an optional extension wire to facilitate catheter exchange and increase the working length beyond 300 cm.

"The TruePath device is an exciting new technology that allows me to effectively penetrate difficult blockages, allowing access to untreated lesions and helping to improve overall patient outcomes," said J. A. Mustapha, MD.

# Arrow NextStep Antegrade Dialysis Catheter

| | |
|---|---|
| COMPANY | Teleflex Incorporated |
| PHONE | (610) 948-2836 |
| WEB | www.teleflex.com |

KEY FEATURES

- Openings are reversed to take better advantage of blood flow dynamics within the heart
- Distal tips of both lumens are significantly separated to help enhance flow and minimize recirculation
- Combines a step-tip catheter's ease of insertion with a split-tip catheter's sustained high flow

Teleflex Incorporated (Limerick, PA) has announced that it has expanded its interventional access portfolio with the Arrow NextStep antegrade catheter, which is now available for sale in the United States. The Arrow NextStep antegrade catheter is a chronic hemodialysis catheter that combines a step-tip catheter's ease of insertion with a split-tip catheter's sustained high flow. Its unique tip is designed for smooth, over-the-wire transitions during catheter insertions and exchanges, the company stated.

To reduce recirculation and deliver high flow, the Arrow NextStep antegrade catheter's tip provides two unique, complementary features: (1) the openings are reversed to take better advantage of blood flow dynamics within the heart; and (2) the distal tips of both lumens are significantly separated to help enhance flow and minimize recirculation.

The Arrow chronic hemodialysis catheter portfolio offers both split-tip and step-tip catheters for both retrograde and antegrade insertion techniques. The Arrow NextStep product family consists of step-tip catheters that can be tunneled using the retrograde or antegrade technique. ■

# Advance 18 PTX Drug-Eluting Balloon

| | |
|---|---|
| COMPANY | Cook Medical |
| PHONE | +353 61 239240 |
| WEB | www.cookmedical.com |

KEY FEATURES

- Combines the benefits of mechanical and drug therapies
- Entire balloon is coated before being folded, allowing for more drug-to-vessel contact
- The proprietary coating process involves no polymers or excipients

Cook Medical (Bloomington, IN) has launched its first drug-eluting balloon (DEB) CE Marked to treat stenotic or occlusive disease in the peripheral vascular system. The Advance 18 PTX will be sold across Europe following CE Mark approval in December.

Based on Cook's drug-eluting technology, the Advance 18 PTX combines the benefits of mechanical and drug therapies, taking advantage of the Advance balloon and the antiproliferative effects of paclitaxel. The proprietary coating process involves no polymers or excipients, and the balloon is coated before being folded, allowing for more drug-to-vessel contact, the company stated.

# Crux Biomedical IVC Filter

| | |
|---|---|
| COMPANY | Crux Biomedical Inc. |
| PHONE | (650) 321-9903 |
| WEB | www.cruxbiomedical.com |

KEY FEATURES

- Bidirectional retrieval
- Versatile and simple-to-use device design
- High procedural success rate

Crux Biomedical Inc. (Menlo Park, CA) announced that it has received CE Mark approval for their inferior vena cava filter (IVCF) with bidirectional retrieval capability. Vena cava filters are designed to trap blood clots that can lead to a potentially fatal pulmonary embolism. The Crux Biomedical IVCF was designed to address the limitations of currently available vena cava filters including perforation, migration, and inability to retrieve the device.

"Crux was able to design a device that is both more versatile and simple to use," stated Tom Fogarty, MD, noted cardiovascular surgeon and Founder of Crux Biomedical.

A recently completed pivotal trial that was performed at 22 centers in the United States, Australia, New Zealand, and Belgium demonstrated favorable results, including an excellent safety profile and a 98% bidirectional retrieval success rate. The company anticipates submission of the device to the US Food and Drug Administration in February and approval in 2012. ■